Small Pharma applies expert intellectual property design to guide academic discovery to commercial product.
Our current project is a rapid-acting antidepressant with potential to transform depression treatment. Existing antidepressants take 6-12 weeks to work, and are ineffective in 40% of sufferers. Our DMT drug candidates have the potential to accelerate recovery through psychedelic assisted therapy.
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $1.2M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Angel CoFu... | acfinvesto... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.04.2017 | - | $1.2M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private C... | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (... | marketscre... |
| 03.06.2021 | Psychedelic healthcare fund Neo Kuma sees early success amid... | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting tha... | tech.eu/br... |
| 01.06.2021 | SMALL PHARMA INC. Small Pharma Inc. : Expands Phase I/IIa C... | LONDON, June 1, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "... | marketscre... |
| 07.04.2017 | Small Pharma Raises £970K in Funding | Small Pharma, a London, UK-based pharmaceutical startup, raised £970k in total funding. The funding... | finsmes.co... |
| - | Psychedelic healthcare fund Neo Kuma sees early success amid... | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting tha... | tech.eu/20... |